The Potential Role of Aerobic Exercise to Modulate Cardiotoxicity of Molecularly Targeted Cancer Therapeutics

Jessica M. Scott, Susan Lakoski, John R. Mackey, Pamela S. Douglas, Mark J. Haykowsky and Lee W. Jones

The Oncologist 2013, 18:221-231.
doi: 10.1634/theoncologist.2012-0226 originally published online January 18, 2013

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://theoncologist.alphamedpress.org/content/18/2/221
The Potential Role of Aerobic Exercise to Modulate Cardiotoxicity of Molecularly Targeted Cancer Therapeutics

JESSICA M. SCOTT, a SUSAN LAKOSKI, b JOHN R. MACKEY, c PAMELA S. DOUGLAS, d MARK J. HAYKOWSKY, c LEE W. JONES d
aNASA Johnson Space Center, Universities Space Research Association, Houston, Texas, USA; bUniversity of Texas Southwestern Medical Center, Dallas, Texas, USA; cUniversity of Alberta, Edmonton, Alberta, Canada; dDuke University Medical Center, Durham, North Carolina, USA

Disclosures of potential conflicts of interest may be found at the end of this article.

Key Words. Exercise • Cardiotoxicity • Molecular therapeutics • Solid malignancies

ABSTRACT

Molecularly targeted therapeutics (MTTs) are the future of cancer systemic therapy. They have already moved from palliative therapy for advanced solid malignancies into the setting of curative-intent treatment for early-stage disease. Cardiotoxicity is a frequent and potentially serious adverse complication of some targeted therapies, leading to a broad range of potentially life-threatening complications, therapy discontinuation, and poor quality of life. Low-cost pleiotropic interventions are therefore urgently required to effectively prevent and/or treat MTT-induced cardiotoxicity. Aerobic exercise therapy has the unique capacity to modulate, without toxicity, multiple gene expression pathways in several organ systems, including a plethora of cardiac-specific molecular and cell-signaling pathways implicated in MTT-induced cardiac toxicity. In this review, we examine the molecular signaling of antiangiogenic and HER2-directed therapies that may underpin cardiac toxicity and the hypothesized molecular mechanisms underlying the cardioprotective properties of aerobic exercise. It is hoped that this knowledge can be used to maximize the benefits of small molecule inhibitors, while minimizing cardiac damage in patients with solid malignancies. The Oncologist 2013;18:221–231

Implications for Practice: Cardiotoxicity, a frequent and devastating adverse complication of some molecularly targeted therapies (MTTs), can lead to potentially life-threatening cardiovascular complications, therapy discontinuation, and poor quality of life. In non-cancer patients with left ventricular dysfunction and heart failure, aerobic exercise is one of the mainstay clinical interventions for the prevention and treatment of cardiovascular disease. However, few studies have investigated the efficacy of aerobic exercise in the prevention and/or treatment of MTT-induced cardiac injury. This topic is of particular importance because cardiac function is a strong predictor of cardiovascular and all-cause mortality, quality of life, and fatigue, and maybe even cancerspecific mortality. Here, we provide a comprehensive overview of cardiac molecular and cell-signaling pathways specific to MTT-induced cardiac toxicity. This review also outlines many pertinent aerobic exercise-induced molecular signaling pathways that may uniquely prevent and/or treat MTT cardiac injury. Overall, information presented in this review provides critical information for basic scientists, clinicians, and exercise oncology researchers who are investigating the application of exercise in cancer control.

INTRODUCTION

The emergence of molecularly targeted therapies (MTTs) has revolutionized the management of solid malignancies. Antiangiogenic and human epidermal growth factor receptor 2 (HER2)-directed MTTs are approved by the U.S. Food and Drug Administration (FDA) for the treatment of several solid malignancies, either as monotherapy or in combination with standard chemotherapy [1, 2]. The biologic selectivities of these drugs were expected to substantially reduce off-target toxicity, although it is now apparent that MTTs cause adverse cardiovascular consequences, such as hypertension and progressive left ventricular (LV) dysfunction, ultimately leading to symptomatic heart failure.

Several excellent reviews have described the biologic and molecular mechanisms underlying MTT-induced cardiotoxicity and risk for cardiotoxicity [1–8]; however, comparatively little attention has been focused on strategies to prevent and/or mitigate anticipated injury. MTTs target multiple cellular pathways including highly coordinated myocardial molecular signaling. Pleiotropic interventions will therefore be required to effectively prevent and/or treat MTT-induced cardiotoxicity. Aerobic exercise therapy has the unique capacity to modulate, without toxicity, multiple gene expression pathways in several organ systems, including a plethora of cardiac-specific molecular and cell-signaling pathways implicated in MTT-in-
duced cardiac toxicity. Here we review molecular signaling of antiangiogenic and HER2-directed therapies that may underpin cardiac toxicity and the hypothesized cardioprotective properties of aerobic exercise.

**THE BIOLOGY OF TYROSINE KINASES**

Receptor tyrosine kinases (RTKs) are enzymes that act as critical mediators of normal cellular signal transduction and regulate diverse cellular processes including cell cycle progression, metabolism, transcription, and apoptosis (reviewed extensively elsewhere [9, 10]). All RTKs are embedded in plasma membranes and consist of an extracellular ligand-binding domain and an intracellular kinase domain. RTKs are not only key regulators of normal cellular processes, but they also are central to malignant transformation and tumor proliferation when constitutively activated via gene amplification, overexpression, or mutations [11]. Strategies for the prevention or interception of deregulated RTK signaling include the development of selective agents that target either the extracellular ligand-binding domain or the intracellular tyrosine kinase binding region [2, 4]. Monoclonal antibodies (mAbs) are designed to inhibit kinase activation by binding to the extracellular portion of RTKs or by binding to growth factor ligands that activate RTKs. Mechanistically, anti-RTK mAbs block the ligand-receptor interaction, thus inhibiting activation of the tyrosine kinase domain, and/or induce downregulation of receptor expression [12]. In contrast, small-molecule tyrosine kinase inhibitors (TKIs) bind to the intracellular portion of RTKs, thereby inhibiting the phosphorylation of downstream substrates.

**MECHANISMS OF HER2-DIRECTED THERAPY**

**CARDIAC INJURY**

Overexpression and/or gene amplification of the RTK HER2 (also known as ErbB2) is present in approximately 20% of women with breast cancer [13], as well as approximately 10% and 5% of patients with non-small cell lung cancer, [14] and gastric cancer, respectively [15]. Randomized trials demonstrate that HER2-directed agents cause significant improvements in disease-free survival and overall survival among women with early [16, 17] and metastatic [18] HER2-positive breast cancer. However, trastuzumab (the first FDA-approved HER2-directed mAb) and pertuzumab (a newer mAb in phase III testing) are associated with cardiac toxicity (Table 1).

**HER2-DIRECTED THERAPY INHIBITION OF CARDIAC MOLECULAR SIGNALING**

We focus here on the putative role of ErbB2 and transforming growth factor β (TGFβ) signaling as major pathways mediating anti-ErbB2 cardiotoxicity (Fig. 1).

**ErbB2**

ErbB2 belongs to the family of human epidermal growth factor (EGF) receptors comprised of the EGF receptor (ErbB1), ErbB2, ErbB3, and ErbB4 [19]. Hyperactivation of the ErbB2/ErbB3/PI3K complex in tumor cells leads to upregulation of the phosphatidylinositol 3-kinase (PI3K)-Akt pathways resulting in cellular proliferation [20], increased mitogen-activated protein kinase (MAPK) activity causing protein hypertrophy [21], and reduced cytostasis via CCAAT/enhancer-binding protein (C/EBPβ) [22]. The antiproliferative activity of HER2-directed therapy is therefore based on disruption of the ErbB2-ErbB3 complex in tumor cells, thus reducing intracellular Akt activity [19, 23] and MAPK signaling [24]. Conversely, HER2-directed therapy dramatically alters cardiomyocyte function and/or survival via inhibition of Nrg1/ErbB/Akt signaling.

The essential role of ErbB2 signaling for cardiomyocyte proliferation was first revealed through germline deletion of ErbB2 receptors in mice, which proved lethal in mid gestation with failure of proper ventricle formation [25]. Transgenic mice with cardiac-specific deletion of ErbB2 after cardiac development survive embryogenesis [25] but develop progressive cardiomyopathy in adulthood [16]. In the healthy heart, neuregulin-1β (Nrg1) is released by endocardial and myocardial endothelial microvascular cells and binds to ErbB4 on cardiomyocytes leading to activation of the ErbB2/ErbB4/PI3K/Akt complex. HER2-directed agents inhibit Nrg1 release [26] and significantly decrease both total and phosphorylated Akt in neonatal rat cardiomyocytes [27], thus potentially limiting cell growth, glucose uptake, and protein regulation [28–30] and ultimately triggering the progression of heart failure [31].

**TGFβ**

During carcinogenesis, TGFβ signaling initially prevents malignant progression via the small mother against decapentaplegic (Smad) pathway [32]. Eventually, malignant cells overexpressing ErbB2 circumvent the growth-suppressive effects of TGFβ by downregulating TGFβ receptors or altering downstream pathways [22]. In the heart, TGFβ regulates ventricular remodeling (cardiomyocyte hypertrophy) via activation of the Smad/3 and 4 complexes and matrix metalloproteinases [33]. Inhibition of ErbB2 signaling with trastuzumab also activates TGFβ and C/EBPβ signaling in breast cancer cells [22]. Whether trastuzumab induces TGFβ and C/EBPβ signaling in cardiomyocytes is unknown; however, increased cardiac TGFβ and C/EBPβ expression results in pathological remodeling [34].

**AEROBIC EXERCISE-INDUCED CARDIOPROTECTION FROM HER2-DIRECTED AGENTS**

Figure 2 outlines the modulation of ErbB and TGFβ signaling through aerobic exercise. The cardioprotective properties of increased Nrg1/ErbB signaling are well described [26, 29]. For example, drug-induced enhancement of myocardial Nrg1/ErbB signaling significantly improved both cardiac performance and survival in four different rodent models of LV failure [31] and induced differentiated cardiomyocytes to proliferate [35]. In vitro studies in isolated cardiac endothelial cells (the main source of Nrg1 in the heart) show that mechanical strain increases endothelial Nrg1 synthesis and release [36], whereas Nrg1 release is directly inhibited by angiotensin II and adrenergic agonists [37]. Aerobic exercise increases endocardial mechanical strain [38] with a concomitant reduction in angiotensin II [39]. Interestingly, Lebrasseur et al. [40] found that resistance or aerobic exercise increased proteolytic processing of mature Nrg1 transmembrane protein to soluble Nrg1 in rat skeletal muscle. Thus, we contend that increased Nrg1 synthesis in the ventricle in response to exercise-induced mechanical stress will evoke suppression of neurohormonal factors, leading to cardioprotection.
Figure 1. Mechanisms underlying HER2-directed therapy cardiotoxicity. Inhibition of ErbB receptors with HER2-directed therapies impacts numerous signaling pathways resulting in suppression of myofilament protein synthesis via the PI3K-Akt pathway (pathway A), suppression of protein hypertrophy via the MAPK pathway (pathway B), suppression of cell survival via Src/Fak pathway (pathway C), suppression of myofilament protein synthesis and upregulation of protein degradation via TGF-β1 and C/EBPβ signaling (pathway D), and alterations in cardiac energy metabolism via downregulation of AMPK (pathway E).

Abbreviations: AMPK, AMP-activated protein kinase; C/EBPβ, CCAAT/enhancer binding protein; Fak, focal adhesion kinase; MAPK, mitogen-activated protein kinase; Nrg1, Neuregulin-1-β; PI3K, phosphatidylinositol 3-kinase; Smad, small mother against decapentaplegic; TGFβ, transforming growth factor β.

Table 1. Incidence of cardiotoxicity in HER2-directed and angiogenesis inhibitor clinical trials

<table>
<thead>
<tr>
<th>Agent</th>
<th>Class</th>
<th>Target</th>
<th>Malignancy</th>
<th>Heart failure</th>
<th>Subclinical decline in ejection fraction (≥ 10%)</th>
<th>Hypertension (≥ grade I)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trastuzumab</td>
<td>mAb</td>
<td>ErbB2</td>
<td>ErbB2 + breast cancer, MGC (phase III)</td>
<td>1.7%–4% (early)</td>
<td>2.1%–14% (early) [89] 10%–18% (advanced) [36, 92–96]</td>
<td>NA</td>
</tr>
<tr>
<td>Lapatinib</td>
<td>TKI</td>
<td>ErbB1, ErbB2</td>
<td>ErbB2 + breast cancer, NSCLC (phase II)</td>
<td>0.2% (advanced)</td>
<td>1.4%–5% (advanced) [97, 98]</td>
<td>4% (advanced) [99]</td>
</tr>
<tr>
<td>Pertuzumab</td>
<td>mAb</td>
<td>ErbB2</td>
<td>ErbB2 + breast cancer (phase II)</td>
<td>9% (advanced)</td>
<td>1.2%–54% (advanced) [91, 100–102]</td>
<td>NA</td>
</tr>
<tr>
<td>Bevacizumab</td>
<td>mAb</td>
<td>VEGF</td>
<td>RCC, NSCLC, glioblastoma, CRC, breast</td>
<td>2.2%–3% (advanced)</td>
<td>2%–14% (early) [103, 104]</td>
<td>2%–12% (early) [106, 109]</td>
</tr>
<tr>
<td>Ramucirumab</td>
<td>mAb</td>
<td>VEGFR</td>
<td>RCC (phase II), breast (phase III)</td>
<td>NA</td>
<td>NA</td>
<td>13.5% (advanced) [111]</td>
</tr>
<tr>
<td>Sunitinib</td>
<td>TKI</td>
<td>VEGFR 1–3, c-kit, PDGFR</td>
<td>RCC, GIST</td>
<td>2.7%–11% (advanced) [62, 112]</td>
<td>4%–47% (advanced) [62, 112]</td>
<td>5%–47% (advanced) [62, 113, 114]</td>
</tr>
<tr>
<td>Sorafenib</td>
<td>TKI</td>
<td>VEGFR 2, PDGFR, Raf1</td>
<td>RCC, melanoma</td>
<td>NA</td>
<td>18.3% (advanced) [115]</td>
<td>7.3%–43% (advanced) [116–119]</td>
</tr>
<tr>
<td>Pazopanib</td>
<td>TKI</td>
<td>VEGFR, c-kit, PDGFR</td>
<td>RCC, breast (phase III)</td>
<td>NA</td>
<td>NA</td>
<td>14%–40% (advanced) [120, 121]</td>
</tr>
<tr>
<td>Cediranib</td>
<td>TKI</td>
<td>VEGFR 1–3, c-kit</td>
<td>RCC, breast, and liver (all phase II)</td>
<td>NA</td>
<td>NA</td>
<td>21%–81% (advanced) [122–124]</td>
</tr>
<tr>
<td>Vandetanib</td>
<td>TKI</td>
<td>VEGFR, EGFR</td>
<td>MTC, NSCLC (phase III), mHRPC (phase II)</td>
<td>NA</td>
<td>NA</td>
<td>14%–29% (advanced) [115–117]</td>
</tr>
<tr>
<td>Motesanib</td>
<td>TKI</td>
<td>VEGFR, PDGFR, c-kit</td>
<td>MBC (Phase II)</td>
<td>NA</td>
<td>9% (advanced) [128]</td>
<td>12% (advanced) [128]</td>
</tr>
<tr>
<td>Axitinib</td>
<td>TKI</td>
<td>VEGFR, PDGFR, c-kit</td>
<td>Pancreatic, (phase III), MBC (phase II)</td>
<td>NA</td>
<td>1.8% (advanced) [129]</td>
<td>7%–27% (advanced) [129, 130]</td>
</tr>
</tbody>
</table>

Abbreviations: CRC, colorectal cancer; GIST, gastrointestinal stromal tumor; HF, heart failure; mAb, monoclonal antibody; MBC, metastatic breast cancer; MGC, metastatic gastric cancer; mHRPC, metastatic hormone-refractory prostate cancer; MTC, metastatic medullary thyroid cancer, NA, not available; NSCLC, non-small-cell lung cancer; RCC, renal cell carcinoma; TKI, tyrosine kinase inhibitor.
Aerobic exercise may also modulate a number of myocar-
dial intracellular processes, thus overcoming HER2-inhibitor
receptor blockade. McMullen et al. [41, 42] elegantly demon-
strated that exercise increases myocardial Akt, with subse-
quent attenuation of pathologic LV remodeling, fibrosis, and
protein degradation. Whether similar processes occur dur-
ing administration of targeted cancer therapeutics has not
been investigated; however, exercise training increases
myocardial PI3K activity [43] with an effective reduction in
infarct size and cardiomyocyte apoptosis in rats subjected
to myocardial ischemia reperfusion [44], as well as improves
lifespan in mice with dilated cardiomyopathy [45]. These in-
vestigations provide evidence for the protective effects of
PI3K/Akt signaling in settings of targeted therapy-induced car-
diac stress.

Finally, aerobic exercise inhibits TGFβ and C/EBPβ signal-
ing to effectively prevent and/or attenuate pathological car-
diac hypertrophy in various mouse models. For instance,
aerobic exercise attenuates isoproterenol-induced increases in
myocardial levels of TGFβ and C/EBPβ mRNA, with parallel in-
hibition of pathological myocardial hypertrophy [34]. Exer-
cise-induced reduction of TGFβ and C/EBPβ expression, in
turn, increases both cardiomyocyte size and cell division re-
sulting in physiological hypertrophy [34]. Interestingly, exer-
cise or experimental downregulation of C/EBPβ expression
has also been shown to upregulate GATA4, a regulator of car-
diomyocyte proliferation during myocardial regeneration in
zebrafish [46]. These data indicate that aerobic exercise inhib-
its TGF-β1 and C/EBPβ expression and upregulates GATA4, ul-
timately leading to modulation of protein degradation and
upregulation of protein synthesis.

In the only human study examining MTTs and exercise to
date, our group found that 16 weeks of supervised aerobic
training failed to attenuate trastuzumab-induced LV dilation
and reduced ejection fraction in patients with HER2-positive
operable breast cancer [47]. This observation is in contrast to
work by us and others demonstrating that aerobic training can
reverse LV remodeling in patients with stable heart failure [48,
49]. These discordant findings were likely due to the fact that
participants in the trastuzumab trial attended an insufficient
number of training sessions and did not receive a high enough
training stimulus to achieve beneficial adaptations.

MECHANISMS OF ANGIOGENESIS INHIBITION DIRECTED
THERAPY-INDUCED CARDIAC INJURY

Angiogenesis, the formation of new capillary blood vessels, is
predominantly regulated via vascular endothelial growth fac-
tor (VEGF) and is fundamental for both physiologic and patho-
logic processes (reviewed extensively in references [50, 51]).
VEGF inhibition, alone or in combination with conventional
chemotherapy, is now approved by the FDA as first-line ther-
apy for a broad range of advanced solid malignancies [50].
The incidence and magnitude of cardiac injury with multtargeted
TKIs is particularly high, whereas treatment with monoclonal
mAbs appears to cause comparably less injury (Table 1).
Figure 3. Mechanisms underlying anti-angiogenic therapy cardiotoxicity. Inhibition of VEGF signaling with tyrosine kinase inhibitor-directed therapies impacts numerous signaling pathways resulting in inhibition of angiogenesis, and protein synthesis and degradation via the PI3K-Akt-NO pathway; and inhibition of cell proliferation and differentiation via the MAPK-ERK pathway. Monoclonal inhibitors include bevacizumab and ramucirumab; multikinase inhibitors include sunitinib, axitinib, pazopanib, motesanib, vadetanib, and sorafenib.

Abbreviations: MAPK, mitogen-activated protein kinase; NO, nitric oxide; PI3K, phosphatidylinositol 3-kinase; VEGF, vascular endothelial growth factor.

Figure 4. Mechanisms underlying anti-angiogenic therapy cardiotoxicity through aerobic exercise. Aerobic exercise induces cardioprotection via upregulation of VEGF expression; a nitric oxide-dependent increase in endothelial progenitor cells; and activation of STAT3 resulting in erythropoietin secretion and binding to cardiac progenitor cells, causing differentiation into endothelial cells.

Abbreviations: CPC, cardiac progenitor cells; MAPK, mitogen-activated protein kinase; NO, nitric oxide; PI3K, phosphatidylinositol 3-kinase; EC, endothelial cell; EPO, erythropoietin; VEGF, vascular endothelial growth factor.
ANTIANGIOGENIC THERAPY INHIBITION OF CARDIAC AND VASCULAR MOLECULAR SIGNALING

Putative pathways underlying the cardiotoxic properties of monoclonal and multitargeted agents are illustrated in Figure 3.

Monoclonal Inhibition

Circulating VEGF binds to its receptors platelet derived growth factor receptor (PDGFR), VEGFR1 (also known as Flt-1), and VEGFR2 (also known as Flk-1 or KDR). Monoclonal therapeutic inhibition of the VEGF pathway is achieved via antibodies targeting a VEGF ligand (e.g., bevacizumab binding to VEGF), decoy receptors for VEGF (e.g., aflibercept), or antibodies targeting the extracellular domain of VEGFRs (e.g., ramucirumab binding to VEGFR2), thus limiting endothelial cell sprouting, migration, proliferation, and tube formation [52]. Of importance, suppression of VEGF/VEGFR signaling causes pathological alterations in cardiac and vascular tissues [53, 54]. For instance, global VEGF knockout in rodents causes embryonic lethality [55], whereas postnatal murine downregulation of myocardial VEGF expression initiates a cascade of events leading to progressive diastolic and systolic LV dysfunction [43]. Cardiac-specific VEGF knockout mice display abnormal cardiac muscle capillarity number [56] and classic features of cardiomyopathy (i.e., reduced cardiac output, fractional shortening, decreased dP/dt) [57]. Physiologically, cardiomyocyte binding of VEGF activates Akt, initiating signaling pathways regulating nitric oxide (NO) synthase, angiogenesis, and progenitor cell differentiation into cardiomyocytes [58–60]. Anti-VEGF agents likely inhibit vascular NO release, thus promoting vasoconstriction, increased peripheral resistance, and increased blood pressure, [53], as well as limiting endothelial progenitor cell (EPC) [59] and cardiac progenitor cell (CPC) [61] development and ultimately restraining cardiomyocyte differentiation. Unfortunately, limited clinical data and mechanistic information are available to substantiate these potential pathways.

Multitargeted Inhibition

Multitargeted TKIs may lead to a greater incidence and magnitude of cardiotoxicity due to binding of multiple proteins and/or downstream pathways (Table 1). For instance, Chu et al. [62] demonstrated that sunitinib, which targets VEGFR1–3, c-kit, and PDGFR, leads to profound structural and functional abnormalities in cardiomyocyte mitochondria, leading to a decrease in ATP production. In addition, blockade of VEGFR2 with TKIs decreases endothelial nitric oxide synthase (eNOS)
occurs via upstream peroxisome proliferator-activated repression in murine cardiac tissue. Increased VEGF expression infarct-induced [69] decrease in VEGF mRNA and protein expression [43]. Aerobic exercise augments the aging-induced [68] and diabetes-induced cardiotoxicity. These conceptual pathways are illustrated in Figure 4. Upregulation of myocardial VEGF using naked DNA gene therapy enhances capillary density and decreases endothelial cell and cardiomyocyte apoptosis, leading to improvements in cardiac function in a diabetic rat model [43]. Aerobic exercise augments the aging-induced [68] and infarct-induced [69] decrease in VEGF mRNA and protein expression in murine cardiac tissue. Increased VEGF expression occurs via upstream peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α) through the transcription factor estrogen-related receptor-α and is independent of hypoxia-inducible factor 1α-inducible VEGF expression [70]. Aerobic exercise rapidly upregulates PGC-1α mRNA in skeletal muscle, with a concomitant increase in mitochondrial content leading to resistance to fatigue and a higher number of oxidative fibers [71]. Thus, because PGC-1α is obligatory for the exercise-induced increase in VEGF expression, it is evident that PGC-1α has a particularly prominent role in regulating training-induced VEGF expression.

An additional putative cardioprotective mechanism is exercise-induced augmentation in the production and mobilization of CPCs and EPCs via acute increases in interleukin-6 (IL-6), NO, and VEGF-dependent mechanisms [72–74]. Aerobic exercise leads to an NO-dependent increase in circulating EPCs in mice and humans [72], thus contributing to neovascularization and vascular repair, leading to improved endothelial function and myocardium recovery after ischemia [75–78]. IL-6 also plays multiple functions in angiogenesis and vascular activation and NO release, promoting vasoconstriction and increased blood pressure [63]. Of significance, the combined cardiac and vascular injury may enhance the severity of cardiac injury. Iizumiya et al. [64] demonstrated that VEGF inhibition contributed to progression from compensatory cardiac hypertrophy to LV failure under hypertensive conditions. Chronic hypertension ultimately leads to a compensatory increase in myocardial muscle mass to maintain normal cardiac output [65]. In both hypertensive and pre-hypertensive states, there is slow but steady hypertrophy of the LV [66], leading to a decreased ability to relax initially during exercise and subsequently at rest [67]. Whether concentric remodeling occurs in patients receiving antiangiogenic therapies has not been investigated.

### ANGIOGENESIS INHIBITION

Aerobic exercise-induced increase in vascular and myocardial VEGF/VEGFR signaling may prevent/treat antiangiogenesis-induced cardiotoxicity. These conceptual pathways are illustrated in Figure 4. Upregulation of myocardial VEGF using naked DNA gene therapy enhances capillary density and decreases endothelial cell and cardiomyocyte apoptosis, leading to improvements in cardiac function in a diabetic rat model [43]. Aerobic exercise augments the aging-induced [68] and infarct-induced [69] decrease in VEGF mRNA and protein expression in murine cardiac tissue. Increased VEGF expression occurs via upstream peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α) through the transcription factor estrogen-related receptor-α and is independent of hypoxia-inducible factor 1α-induced VEGF expression [70]. Aerobic exercise rapidly upregulates PGC-1α mRNA in skeletal muscle, with a concomitant increase in mitochondrial content leading to resistance to fatigue and a higher number of oxidative fibers [71]. Thus, because PGC-1α is obligatory for the exercise-induced increase in VEGF expression, it is evident that PGC-1α has a particularly prominent role in regulating training-induced VEGF expression.
remodeling and may stimulate EPC proliferation, migration, and tube formation following exercise [73, 79].

Importantly, this upregulation in EPCs and CPCs has been implicated in cardiomyocyte healing processes. Kolwicz et al. [80] found that exercise increased CPC proliferation by ~200% and augmented the presence of KIT-positive cells (a stem cell factor crucial for the mobilization of progenitor cells to sites of injury) in the heart. Together with signal transducer and activator of transcription 3 (STAT3), this exercise-induced increase in CPC proliferation may play a key role in cardiomyocyte proliferation, differentiation, and survival [81]. STAT3 activation has been shown to mediate cardiac hypertrophy and protect cells in response to cardiomyopathy induced by ischemia or drug treatment [82–84]. Significantly, exercise increases STAT3 activation [85, 86], causing release of erythropoietin into the cardiac microenvironment that, in turn, binds to CPCs, causing differentiation into endothelial cells [87]. Presumably, these endothelial cells can then be activated by VEGF to express matrix metalloproteinases, which degrade the vascular basement membrane to form new capillary networks [88]. Collectively, we speculate that aerobic exercise may increase PGC-1α and VEGF secretion and STAT3 activation, with the resultant release, mobilization, and homing of CPCs during angiogenesis inhibitor therapy.

**CONCLUSION**

Molecularly targeted therapeutics are the future of cancer systemic therapy; they have already moved from palliative therapy for advanced solid malignancies into the setting of curative-intent treatment for early-stage disease. Cardiotoxicity is a frequent and potentially serious adverse complication of some targeted therapies, leading to a broad range of potentially life-threatening complications, therapy discontinuation, and poor quality of life. Low-cost, multitargeted interventions are therefore urgently required to mitigate these adverse consequences. Evidence reviewed here indicates that aerobic exercise is a nontoxic, pleiotropic therapy that affects diverse cardiac signaling pathways implicated in the cardiotoxicity induced by anti-HER2 and antiangiogenic therapy. It is important to stress that the current evidence base is emergent with a small number of studies; many areas of MTT-induced cardiotoxicity remain to be defined and addressed. A summary of future investigations needed to define the nature and magnitude of the cardioprotective effects of exercise in the setting of MTT is provided in Table 2. Future challenges for research investigating the effects of aerobic exercise in MTT-induced cardiac toxicity are provided in Table 3.

Although clinical and research interest in aerobic exercise has increased dramatically over the past decade, a more thorough understanding of the myocardial signaling pathways activated by exercise will be needed to improve cardiovascular outcomes. Collectively, such research will lead to mechanistically driven clinical trials. Importantly, adequately powered multicenter randomized controlled trials are required to evaluate the relative efficacy of aerobic exercise training to prevent/treat cardiotoxicity. These investigations, in turn, will inform exercise prescription rehabilitation guidelines for patients with cancer, whereby the most effective exercise intensity and timing (before, during, or following therapy) are established. We anticipate that exercise will complement molecularly targeted therapeutics to improve the health and longevity of patients with solid malignancies.

**ACKNOWLEDGMENTS**

This work is supported in part by grants from the National Cancer Institute (CA143254, CA142566, CA138634, CA133895, CA164751 to L.W.J.), funds from George and Susan Beischer (L.W.J.), and a Natural Sciences and Engineering Research Council postdoctoral fellowship (J.M.S.).

**AUTHOR CONTRIBUTIONS**

**Conception/Design:** Jessica M. Scott, Lee W. Jones

**Manuscript writing:** Jessica M. Scott, Susan Lakoski, John R. Mackey, Pamela S. Douglas, Mark J. Haykowsky, Lee W. Jones

**Final approval of manuscript:** Jessica M. Scott, Susan Lakoski, John R. Mackey, Pamela S. Douglas, Mark J. Haykowsky, Lee W. Jones

**DISCLOSURES**

John R. Mackey: Roche Oncology; Pamela S. Douglas: Atritech/Boston Scientific, Edwards Lifesciences (RF); CardioDX, Universal Oncology (OI). The authors indicated no financial relationships.

**REFERENCES**


19. Hynes NE, Lane HA. ERBB receptors and can-
Targeted Therapy, Cardiotoxicity, and Exercise


84. Kunisada K, Negoro S, Tone E et al. Signal transducer and activator of transcription 3 in the heart transduces not only a hypertrophic signal but a pro-apoptotic signal that leads to cell death. J Mol Cell Cardiol 2006;38:739–749.


86. Toth KG, McKay BR, De Lisio M et al. IL-6 induced STAT3 signalling is associated with the proliferation of human muscle satellite cells following acute muscle damage. PLoS One 2011;6:e17392.


107. Ratain MJ, Eisen T, Stadler WM et al. Phase II


References

This article cites 135 articles, 67 of which you can access for free at:
http://theoncologist.alphamedpress.org/content/18/2/221#BIBL